Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

被引：0

作者：

Kim A. Papp

Melinda Gooderham

Ignacio Dei-Cas

Adriana LopezTello

Juan C. Garcia-Rodriguez

Carmen Yris Taveras

Azucena Hernández Rousselin

Alberto Lavieri

Mónica Maiolino

Delfina Guadalupe Villanueva Quintero

Lenka Rihakova

Mariano Salibe

Wilfran Pertuz

机构：

[1] K Papp Clinical Research and Probity Medical Research,SKiN Centre for Dermatology and Probity Medical Research

[2] Peterborough and Queen’s University,HIGA Presidente Perón, Servicio de Dermatología, Facultad Medicina UBA

[3] Psoriasis BsAs,undefined

[4] NEKI Servicios Medicos,undefined

[5] Vicente Guerreo,undefined

[6] DermaAdvance Center,undefined

[7] Hospital Regional Universitario Jose Maria Cabral Y Baez,undefined

[8] Hospital Roosevelt,undefined

[9] Calzada Roosevelt,undefined

[10] Private Clinic,undefined

[11] Consultorios Médicos Dr Bouzo,undefined

[12] Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflamatorias) Sociedad Civil,undefined

[13] Novartis Pharmaceuticals Canada Inc.,undefined

[14] Novartis Argentina S.A.,undefined

[15] Novartis Pharma Logistics,undefined

[16] Inc.,undefined

[17] Panama,undefined

来源：

Dermatology and Therapy | 2023年 / 13卷

关键词：

Latin America; Plaque psoriasis; PURE registry; Real-world; Secukinumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：269 / 283

页数：14

共 50 条

[41] Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
Pan Ran
Wang Xiaolun
Shu Min
Das Jaydeep
Kalra Manik
Wang Zhidong
中华医学杂志英文版, 2022, 135 (01) : 11 - 19
[42] Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
Armstrong, April W. W.
Fitzgerald, Timothy
McLean, Robert R. R.
Teeple, Amanda
Uy, Jonathan P. P.
Olurinde, Mobolaji
Rowland, Katelyn
Guo, Lin
Shan, Ying
Duffin, Kristina Callis
DERMATOLOGY AND THERAPY, 2023, 13 (02) : 629 - 640
[43] ADHERENCE AND PERSISTENCE AMONG US PATIENTS INITIATING SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
Feldman, S. R.
Zhao, Y.
Gray, S.
Montejano, L. B.
Lin, F.
Herrera, V
VALUE IN HEALTH, 2017, 20 (05) : A159 - A159
[44] Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
Pan, Ran
Wang, Xiaolun
Shu, Min
Das, Jaydeep
Kalra, Manik
Wang, Zhidong
CHINESE MEDICAL JOURNAL, 2022, 135 (01) : 11 - 19
[45] Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Russo, Filomena
Galluzzo, Marco
Stingeni, Luca
Persechino, Severino
Zichichi, Leonardo
Conti, Andrea
Giofre, Claudia
Dini, Valentina
Vispi, Martina
Atzori, Laura
Cattaneo, Angelo
Parodi, Aurora
Bardazzi, Federico
Stinco, Giuseppe
Dapavo, Paolo
Girolomoni, Giampiero
Musumeci, Maria Letizia
Papini, Manuela
Venturini, Marina
Dastoli, Stefano
Di Nuzzo, Sergio
Fargnoli, Maria Concetta
Pagnanelli, Gianluca
Bernardini, Nicoletta
Gambini, Daniele Mario
Malagoli, Piergiorgio
Mazzatenta, Carlo
Peris, Ketty
Zalaudek, Iris
Fabbrocini, Gabriella
Loconsole, Francesco
Vassallo, Camilla
Pietroleonardo, Lucia
Prignano, Francesca
Franchi, Chiara
Offidani, Anna Maria
Bonifati, Claudio
Di Lernia, Vito
Gigante, Giovanni
Bartezaghi, Marta Silvia
Franchi, Matteo
Ursoleo, Paola
Aloisi, Elisabetta
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 3561 - 3574
[46] Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry
Egeberg, A.
Iversen, L.
Gniadecki, R.
Hvid, L.
Dam, T. N.
Bryld, L. E.
Skov, L.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (07) : 1183 - 1187
[47] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
Cai Lin
Zhang Jian-Zhong
Yao Xu
Gu Jun
Liu Quan-Zhong
Zheng Min
Zhang Shi-Fa
Xu Jin-Hua
Li Cheng-Xin
Cheng Hao
Guo Qing
Pan Wei-Li
Li Shen-Qiu
Li Ruo-Yu
Guo Zai-Pei
Song Zhi-Qi
Li Shan-Shan
Dong Xiu-Qin
Wang Linda
Fu Rong
Regnault Pascaline
Charef Pascal
Mazur Rafal
Patekar Manmath
中华医学杂志英文版, 2020, 133 (22) : 2665 - 2673
[48] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
Cai, Lin
Zhang, Jian-Zhong
Yao, Xu
Gu, Jun
Liu, Quan-Zhong
Zheng, Min
Zhang, Shi-Fa
Xu, Jin-Hua
Li, Cheng-Xin
Cheng, Hao
Guo, Qing
Pan, Wei-Li
Li, Shen-Qiu
Li, Ruo-Yu
Guo, Zai-Pei
Song, Zhi-Qi
Li, Shan-Shan
Dong, Xiu-Qin
Wang, Linda
Fu, Rong
Regnault, Pascaline
Charef, Pascal
Mazur, Rafal
Patekar, Manmath
CHINESE MEDICAL JOURNAL, 2020, 133 (22) : 2665 - 2673
[49] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
Klimes, J.
Mollon, P.
Graham, C.
Rajnoch, J.
Dostal, F.
Skalicky, D.
Jordan, P.
Depta, J.
VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
[50] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
Tzanetakos, C.
Kourlaba, G.
Hatzikou, M.
Antoniou, C.
Ioannides, D.
Lefaki, I.
Petridis, A.
Rigopoulos, D.
Roussaki-Schulze, V.
Sotiriadis, D.
Maniadakis, N.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62

← 1 2 3 4 5 →